Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
about
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesVTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDabigatran approaching the realm of heparin-induced thrombocytopeniaThe evolution of anticoagulant therapyPregnancy and vascular liver diseaseGuidance for the treatment of deep vein thrombosis and pulmonary embolismGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismDirect oral anticoagulants in hypercoagulable states.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Atomic description of the immune complex involved in heparin-induced thrombocytopeniaMassive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesProspective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.A cohort study investigating compliance with guidelines for platelet count monitoring during heparin thromboprophylaxis.Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.The management of suspected heparin-induced thrombocytopenia in US hospitals.Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis.Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital.Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia.Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting.Heparin-induced thrombocytopenia following hip and knee arthroplasty.Alternative monitoring of argatroban using plasma-diluted thrombin time.Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: a case report.Successful management of heparin-induced thrombocytopenia using argatroban in a very old woman: a case reportA modified technique for implantation of the HeartWare™ left ventricular assist device when using bivalirudin anticoagulation in patients with acute heparin-induced thrombocytopenia.Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation.Apparent argatroban resistance in a patient with elevated factor VIII levels.Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia.Thrombocytopenia caused by low-dose heparin supplementation of parenteral nutrition solutionProspective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia.Evaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia.High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies.Heparin induced thrombocytopenia: review.Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies.Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinuxContemporary treatment of immune thrombocytopenia.Non-transient "self-sustaining" heparin-induced thrombocytopenia: 4-year persistence of a platelet-activating PF4/heparin-antibody status without heparin exposure.
P2860
Q24632927-8FC5AAA6-4E26-42B2-9410-9699E28004F2Q24632982-BCE80B57-AA63-464D-A4D8-434735B83A98Q24633053-F11308B0-9C95-41AC-AA6B-1C444A52A0F8Q26744261-9AE81458-E196-47EA-B8BC-C1BC0CCD2C71Q26771859-31A20830-3396-4C9E-A7EA-47C635C18063Q27025448-A77DF536-AAF4-4A63-87E0-00DF1C9BE892Q28078989-804DD8AD-ECB2-4DEE-A5BE-4F839192E9F7Q28079081-B23B9CB6-330C-480B-9C08-63C5A241E950Q30275936-9D4BA023-BABC-4034-BB3A-7708EC7E6D9CQ30276550-05D09E6A-7AB0-4388-99F3-B8C7CC728735Q30665349-0ECFD477-DC81-481B-970D-E0FDA91201BBQ33166993-18DC4CE0-1EE6-400E-B8E3-349407EAD917Q33399576-ADC5ADB2-77D3-42D4-A588-9A3D809349EDQ33401095-EA61900D-61D0-4740-85DC-8CDC2089DCB8Q33401354-223E8AD5-7867-4518-91AA-BD68212C0539Q33402572-600EDE8A-B79D-4F7A-B6B8-D5D4F2E02E1CQ33402813-69A656E0-7F82-4EF4-983C-2B57C98EFBE8Q33403263-154743F2-FD03-4538-AA0A-46D01684DC66Q33403395-37B06660-622D-4B24-A71C-A13289768E75Q33403703-037A860A-EA79-4004-B9DC-3246356AD3D4Q33404467-FAD09F6C-7C40-4A66-BCE5-E05CC7855086Q33405047-589129A7-9B5C-414F-9190-55C7C9CA0EC4Q33405315-B42CC528-FC40-4E76-8FAD-BADA8835E481Q33405846-4E2FD41C-965E-4334-9490-AFE2C6548573Q33406400-03E38033-5923-4E3A-B6CC-E1E6C1885B2DQ33406618-751B1727-9436-4443-A02D-B01AD5E4ADDDQ33406662-DED636D4-1C75-48DF-99D0-7BF847B073F3Q33407383-ECA4A9AA-13A4-423A-B70E-ACE15FED69B5Q33407767-5148785B-EC32-4D1E-A337-11977595F160Q33408201-AAF56503-34C6-4C4B-9492-42F37AB7A8A8Q33408471-6FF507A4-A6C6-4C30-9C65-841783ABB34EQ33408885-FD6013BC-9BC4-4A0F-9E6E-12ED621E826CQ33409277-ED9678E3-6DB4-44FA-87A5-7A448E93764FQ33409923-BDF948B7-EF73-45E3-AC5D-F9EFE940B7C9Q33410017-711DF751-61B8-4677-B484-45AE6FD3D348Q33410083-5A16CA2B-6183-4A30-AF07-5820F74B390EQ33410242-E2369C70-3F27-4772-9B76-F6FC5D18DC3BQ33410578-9CBF87AB-4E1E-48FE-9305-0361AD1F4EE1Q33410653-9BAF294C-1943-4655-A3B6-EF35A24D3117Q33411546-56A377A4-2810-4BB7-8AFB-7D169714544B
P2860
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Treatment and prevention of he ...... Clinical Practice Guidelines.
@ast
Treatment and prevention of he ...... Clinical Practice Guidelines.
@en
type
label
Treatment and prevention of he ...... Clinical Practice Guidelines.
@ast
Treatment and prevention of he ...... Clinical Practice Guidelines.
@en
prefLabel
Treatment and prevention of he ...... Clinical Practice Guidelines.
@ast
Treatment and prevention of he ...... Clinical Practice Guidelines.
@en
P2093
P2860
P356
P1433
P1476
Treatment and prevention of he ...... Clinical Practice Guidelines.
@en
P2093
Antonio L Dans
Bruce L Davidson
Lisa K Moores
Lori-Ann Linkins
Mark Crowther
Robert Bona
P2860
P304
e495S-e530S
P356
10.1378/CHEST.11-2303
P407
P433
P50
P577
2012-02-01T00:00:00Z